Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Long-term interferon monotherapy reduces the risk of HCV-associated hepatocellular carcinoma.

Takeyasu M, Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2012 Aug;84(8):1199-207. doi: 10.1002/jmv.23288.

PMID:
22711347
2.

Long-term outcome after interferon therapy in elderly patients with chronic hepatitis C.

Arase Y, Ikeda K, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Koyama R, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2007;50(1):16-23.

PMID:
17164553
3.

Amino acid substitutions in hepatitis C virus core region predict hepatocarcinogenesis following eradication of HCV RNA by antiviral therapy.

Akuta N, Suzuki F, Hirakawa M, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2011 Jun;83(6):1016-22. doi: 10.1002/jmv.22094.

PMID:
21503914
4.

Amino acid substitutions in the hepatitis C Virus core region and lipid metabolism are associated with hepatocarcinogenesis in nonresponders to interferon plus ribavirin combination therapy.

Seko Y, Akuta N, Suzuki F, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

Intervirology. 2013;56(1):13-21. doi: 10.1159/000339993. Epub 2012 Aug 16.

PMID:
22907167
5.

Amino acid substitutions in the hepatitis C virus core region are the important predictor of hepatocarcinogenesis.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

Hepatology. 2007 Nov;46(5):1357-64.

PMID:
17657816
6.

Hepatocyte steatosis is an important predictor of response to interferon (IFN) monotherapy in Japanese patients infected with HCV genotype 2a: Virological features of IFN-resistant cases with hepatocyte steatosis.

Akuta N, Suzuki F, Suzuki Y, Sezaki H, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kobayashi M, Kumada H.

J Med Virol. 2005 Apr;75(4):550-8.

PMID:
15714492
7.

Virological and biochemical features in elderly HCV patients with hepatocellular carcinoma: amino acid substitutions in HCV core region as predictor of mortality after first treatment.

Ogura S, Akuta N, Hirakawa M, Kawamura Y, Yatsuji H, Sezaki H, Hosaka T, Kobayashi M, Suzuki F, Suzuki Y, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

Intervirology. 2009;52(4):179-88. doi: 10.1159/000225193. Epub 2009 Jun 17.

PMID:
19546575
8.

A prospective comparison of the effect of interferon-alpha and interferon-beta treatment in patients with chronic hepatitis C on the incidence of hepatocellular carcinoma development.

Kashiwagi K, Furusyo N, Kubo N, Nakashima H, Nomura H, Kashiwagi S, Hayashi J.

J Infect Chemother. 2003 Dec;9(4):333-40.

PMID:
14691655
9.

Interferon therapy for 2 years or longer reduces the incidence of hepatocarcinogenesis in patients with chronic hepatitis C viral infection.

Arase Y, Ikeda K, Tsubota A, Suzuki F, Suzuki Y, Saitoh S, Kobayashi M, Akuta N, Someya T, Hosaka T, Sezaki H, Kobayashi M, Kumada H.

Intervirology. 2004;47(6):355-61.

PMID:
15564748
10.
11.

Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.

Akuta N, Suzuki F, Seko Y, Kawamura Y, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Hara T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

Hepatology. 2012 Dec;56(6):2134-41. doi: 10.1002/hep.25949.

PMID:
22806754
12.

Analysis of background factors influencing long-term prognosis of patients with chronic hepatitis C treated with interferon.

Yoneyama K, Yamaguchi M, Kiuchi Y, Morizane T, Shibata M, Mitamura K.

Intervirology. 2002;45(1):11-9.

PMID:
11937766
13.

Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study.

Ikeda K, Marusawa H, Osaki Y, Nakamura T, Kitajima N, Yamashita Y, Kudo M, Sato T, Chiba T.

Ann Intern Med. 2007 May 1;146(9):649-56.

PMID:
17470833
15.

Risk factors for the development of hepatocellular carcinoma among patients with chronic hepatitis C who achieved a sustained virological response to interferon therapy.

Tokita H, Fukui H, Tanaka A, Kamitsukasa H, Yagura M, Harada H, Okamoto H.

J Gastroenterol Hepatol. 2005 May;20(5):752-8.

PMID:
15853990
16.

Efficacy of interferon monotherapy in young adult patients with chronic hepatitis C virus infection.

Uka K, Suzuki F, Akuta N, Sezaki H, Suzuki Y, Hosaka T, Someya T, Kobayashi M, Saitoh S, Arase Y, Ikeda K, Kumada H.

J Gastroenterol. 2006 May;41(5):470-5.

PMID:
16799889
17.
18.

The effect of retreatment with interferon-alpha on the incidence of hepatocellular carcinoma in patients with chronic hepatitis C.

Toyoda H, Kumada T, Nakano S, Takeda I, Sugiyama K, Kiriyama S, Sone Y, Hisanaga Y.

Cancer. 2000 Jan 1;88(1):58-65.

PMID:
10618606
19.

Association between mutations in the core region of hepatitis C virus genotype 1 and hepatocellular carcinoma development.

Nakamoto S, Imazeki F, Fukai K, Fujiwara K, Arai M, Kanda T, Yonemitsu Y, Yokosuka O.

J Hepatol. 2010 Jan;52(1):72-8. doi: 10.1016/j.jhep.2009.10.001. Epub 2009 Oct 23. Erratum in: J Hepatol. 2010 Apr;52(4):620.

PMID:
19910070
20.

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.

Akuta N, Suzuki F, Kawamura Y, Yatsuji H, Sezaki H, Suzuki Y, Hosaka T, Kobayashi M, Kobayashi M, Arase Y, Ikeda K, Kumada H.

J Med Virol. 2008 Aug;80(8):1354-62. doi: 10.1002/jmv.21202.

PMID:
18551609

Supplemental Content

Support Center